
    
      Prospective phase II clinical trial to evaluate technical and oncological safety of LG for
      AGC

      LG procedure for AGC:

      D2 lymphadenectomy Total omentectomy for tumor with serosa exposure under laparoscopic
      exploration

      Primary end point: 3 year disease free survival secondary end point: postoperative outcomes,
      morbidity and mortality, 3,5 and 7 year overall survival, Quality of life, recurrence pattern

      Study duration: 7 years(enrollment: 4year, follow-up: 3year)
    
  